Method for the Treatment of Depression and Anxiety

**Title:** Method for the Treatment of Depression and Anxiety

**Invention:** This technology relates to a modified version of SHU9119, a peptide chain that is known to interact with Melanocortin. This modified version of SHU9119 can antagonize the Melanocortin 5 Receptor (MC5R), potentially enabling rapidly-acting drugs to target these receptors and provide therapeutic relief for those suffering from depression and other mood disorders.

**Background:** Current treatments for depression include drugs with delayed therapeutic onset. This technology has the potential to fill this unmet need with a therapy that is specific to MC5R for treating depression and other mood disorders.

**Applications:**
- Pharmaceutical compound for the treatment of depression, anxiety, and other mood disorders

**Advantages:**
- Targets specific receptor minimizes undesirable side effects
- May achieve therapeutic effect in less time than alternative pharmacological interventions.

**Licensing Manager:**
Laura Silva
LauraS@tla.arizona.edu
(520) 626-1557

**Inventors**
- Horst Kessler
- Minying Cai
  Research Professor, Chemistry and Biochemistry